In summary, adiponectin may be associated with GDM development through impaired insulin sensitivity, decreased β cell mass and attenuated anti-inflammatory capacity, thus representing a potential target for treatment or prevention of GDM [195] (Figure 6). Here, ADIPOQ is linked to gestational diabetes.